-
Man City win as Inter stay perfect, Barca held in Champions League
-
French superstar DJ Snake wants new album to 'build bridges'
-
Barca rescue draw at Club Brugge in six-goal thriller
-
Foden hits top form as Man City thrash Dortmund
-
NBA officials brief Congress committee over gambling probe
-
Inter beat Kairat Almaty to maintain Champions League perfection
-
Newcastle sink Bilbao to extend Champions League winning run
-
Wall Street stocks rebound after positive jobs data
-
LPGA, European tour partner with Saudis for new Vegas event
-
Eyes turn to space to feed power-hungry data centers
-
Jazz lose Kessler for season with shoulder injury
-
League scoring leader Messi among MLS Best XI squad
-
MLS bans Suarez for Miami's winner-take-all playoff match
-
McIlroy appreciates PGA of America apology for Ryder Cup abuse
-
Garnacho equaliser saves Chelsea in Qarabag draw
-
Promotions lift McDonald's sales in tricky consumer market
-
Five things to know about New York's new mayor
-
Anisimova beats Swiatek to reach WTA Finals last four
-
US Supreme Court appears skeptical of Trump tariff legality
-
AC Milan post third straight annual profit on day of San Siro purchase
-
Angelina Jolie visits Ukrainian frontline city, media reports say
-
UN says forests should form key plank of COP30
-
Star designer Rousteing quits fashion group Balmain
-
Mexico's Sheinbaum steps up cartel fight after murder of anti-narco mayor
-
Attack on funeral in Sudan's Kordofan region kills 40: UN
-
Key PSG trio set for spell on sidelines
-
Democrats punch back in US elections - and see hope for 2026
-
BMW reports rising profitability, shares jump
-
US Supreme Court debates legality of Trump's tariffs
-
Bolivia Supreme Court orders release of jailed ex-president Jeanine Anez
-
Wall Street stocks rise after positive jobs data
-
'Hostage diplomacy': longstanding Iran tactic presenting dilemma for West
-
Rybakina stays perfect at WTA Finals with win over alternate Alexandrova
-
Le Garrec welcomes Dupont help in training for Springboks showdown
-
Brussels wants high-speed rail linking EU capitals by 2040
-
Swiss business chiefs met Trump on tariffs: Bern
-
At least 9 dead after cargo plane crashes near Louisville airport
-
France moves to suspend Shein website as first store opens in Paris
-
Spain's exiled king recounts history, scandals in wistful memoir
-
Wall Street stocks steady after positive jobs data
-
Trump blasts Democrats as government shutdown becomes longest ever
-
Indian pilgrims find 'warm welcome' in Pakistan despite tensions
-
Inter and AC Milan complete purchase of San Siro
-
Swedish authorities inspect worksite conditions at steel startup Stegra
-
Keys withdraws from WTA Finals with illness
-
Prince Harry says proud to be British despite new life in US
-
BMW boosts profitability, welcomes Nexperia signals
-
EU strikes last-ditch deal on climate targets as COP30 looms
-
Stocks retreat as tech bubble fears grow
-
Shein opens first permanent store amid heavy police presence
UK researchers cure man who had Covid for 411 days
British researchers announced Friday they have cured a man who was continually infected with Covid for 411 days by analysing the genetic code of his particular virus to find the right treatment.
Persistent Covid infection -- which is different to long Covid or repeated bouts of the disease -- occurs in a small number of patients with already weakened immune systems.
These patients can test positive for months or even years with the infection "rumbling along the whole time", said Luke Snell, a physician specialising in infectious diseases at Guy's and St Thomas' NHS Foundation Trust.
The infections can pose a serious threat because around half of patients also have persistent symptoms such as lung inflammation, Snell told AFP, adding that much remains unknown about the condition.
In a new study published in the journal Clinical Infectious Diseases, a team of researchers at Guy's and St Thomas' NHS Foundation Trust and King's College London describe how a 59-year-old man finally overcame his infection after more than 13 months.
The man, who has a weakened immune system due to a kidney transplant, caught Covid in December 2020 and continued to test positive until January this year.
To discover whether he had contracted Covid numerous times or if it was one persistent infection, the researchers used a rapid genetic analysis with nanopore sequencing technology.
The test, which can deliver results in as little as 24 hours, showed the man had an early B.1 variant which was dominant in late 2020 but has since been replaced by newer strains.
Because he had this early variant, the researchers gave him a combination of the casirivimab and imdevimab monoclonal antibodies from Regeneron.
Like most other antibody treatments, the treatment is no longer widely used because it is ineffective against newer variants such as Omicron.
But it successfully cured the man because he was battling a variant from an earlier phase of the pandemic.
- Resistant to treatment -
"The very new variants that are increasing in prevalence now are resistant to all the antibodies available in the UK, the EU and now even the US," Snell said.
The researchers used several such treatments to try to save a seriously ill 60-year-old man in August this year who had been infected since April.
However none worked.
"We really thought he was going to die," Snell said.
So the team crushed up two antiviral treatments not previously used together -- Paxlovid and remdesivir -- and administered them to the unconscious patient via a nasal tube, according to a non-peer-reviewed preprint study on the website ResearchSquare.
"Miraculously he cleared and perhaps this is now the avenue for how we treat these very difficult persistent infections," Snell said, emphasising that this treatment may not translate for normal Covid cases.
At the ECCMID conference in April, the team announced the longest-known persistent infection in a man who tested positive for 505 days before his death.
That "very sad case" came earlier in the pandemic, Snell said, adding that he was grateful there were now so many more treatment options available.
N.Shalabi--SF-PST